- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04054544
Gluten Challenge Study in Celiac Disease Participants (MK-0000-402)
June 1, 2022 updated by: Merck Sharp & Dohme LLC
A Gluten Challenge Study to Characterize Peripheral Blood and Intestinal Gluten-specific CD4+ T Cell Subsets in Patients With Celiac Disease
This is a gluten challenge study to characterize peripheral blood and intestinal gluten specific cluster of differentiation 4 glycoprotein (CD4+) thymus lymphocyte (T cell) subsets in participants with Celiac Disease
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This is a multi-site, open-label gluten challenge study to characterize peripheral blood and intestinal gluten specific CD4+ T cell subsets in participants with celiac disease (CeD).
Participants will receive 8 grams (g) of gluten daily for 13 consecutive days.
Blood samples will be taken at pre-dose, Day 6, and Day 14. Duodenal biopsy samples will also be collected on Day 14. Participants will also complete a symptom diary.
Study Type
Interventional
Enrollment (Actual)
18
Phase
- Early Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital ( Site 0001)
-
Boston, Massachusetts, United States, 02215
- Beth Israel Deaconess Medical Center ( Site 0002)
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Participant must have documented diagnosis with celiac disease (CeD) by duodenal/jejunal biopsy at least 6 months prior to entrance into the study.
- Participant must be on a gluten-free diet (GFD) for at least the past 12 months.
- Female participants must not be pregnant or breastfeeding. Women of childbearing potential (WOCBP) must use an acceptable contraceptive method or abstain from heterosexual intercourse.
- Must be Human leukocyte antigen (HLA)-DQ2.5 positive, assessed at screening. If participants have already been genotyped, results from previous testing may be used in lieu of genotyping at screening.
- Has anti-tissue transglutaminase (anti-tTG) <2x upper limit of normal (ULN) as measured by serology.
- Be judged to be in good health based on medical history, physical examination (including a targeted neurological exam), versus (vs.) measurements and electrocardiogram (ECG) performed prior to treatment allocation.
- Have a body mass index (BMI) 18-35 kg/m^2, inclusive.
Exclusion Criteria:
- Has any chronic active gastrointestinal (GI) disease (e.g., clinically active CeD despite being on GFD for past 12 months, Crohn's disease, ulcerative colitis, lymphocytic colitis). Inactive, stable/well-treated lactose intolerance, Fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAP) intolerance, gastroesophageal reflux disease (GERD), and irritable bowel syndrome (IBS) are allowed.
- Has clinically active endocrine, gastrointestinal (other than CeD), cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases. Participants with a remote history of uncomplicated medical events or stable medical diseases with no symptoms and stable treatment for the past >3 months may be enrolled in the study at the discretion of the investigator.
- Is mentally or legally incapacitated, has significant emotional problems at the time of prestudy (screening) visit or expected during the conduct of the study or has a history of clinically significant psychiatric disorder within the last 5 years. Participants who have had situational depression may be enrolled in the study at the discretion of the investigator.
- Participant has an estimated Glomerular Filtration Rate (eGFR) ≤80 mL/min/1.73 m^2 at the screening visit based on the Cockcroft-Gault (CG) equation
- Has a history of significant multiple and/or severe allergies (e.g., food, drug, latex allergy), or has had an anaphylactic reaction or systemic allergic reaction to prescription or nonprescription drugs or food.
- Subject has a history of severe acute symptomatic reactions to sporadic gluten ingestion.
- Is positive for hepatitis B surface antigen, hepatitis C antibodies or human immunodeficiency virus (HIV).
- Had major surgery, donated or lost 1 unit of blood (approximately 500 mL) within 4 weeks prior to the prestudy (screening) visit.
- Is on Coumadin™ or other anticoagulants.
- Is unable to refrain from or anticipates the use of systemic anti-inflammatory, immunosuppressive, or immunomodulatory medications, which may include ibuprofen > 2400 mg/day, naproxen >750 mg/day, prednisone >10 mg/day, or methylprednisolone > 8 mg/day, within 48 hours prior to the start of and throughout the entire gluten challenge.
- Has participated in another investigational study within 4 weeks (or 5 half-lives, whichever is greater) prior to the prestudy (screening) visit. The window will be derived from the date of the last visit in the previous study.
- Has a corrected QT (QTc) interval ≥470 msec (for males) or ≥480 msec (for females).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Gluten challenge
Participants will receive a gluten 4 g powder twice daily (BID), for 13 consecutive days
|
Gluten powder 4g oral BID
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of α1- and α2-gliadin-reactive CD4+ T Cells in Peripheral Blood Before Gluten Challenge
Time Frame: Baseline (Day 1, pre-dose)
|
Peripheral blood mononuclear cells (PBMC) collected prior to gluten challenge were stained with phycoerythrin (PE)-labeled human leukocyte antigen (HLA)-DQ2.5:
gluten tetramers (DQ2.5-glia-α1 and DQ2.5-glia-α2) to identify antigen-specific cluster of differentiation (CD)4-positive thymus lymphocyte (T cells) reactive to gliadin (tetramer+ T cells) by flow cytometry.
PBMC were also labeled with a 20-antibody panel for cell surface antigen staining to further define tetramer+ T cell subsets.
Antigens included in the analysis were CD25, CD38, CD39, programmed cell death receptor 1 (PD-1), and integrin beta-7 (B7).
|
Baseline (Day 1, pre-dose)
|
Percentage of α1- and α2-gliadin-reactive CD4+ T Cells in Peripheral Blood After Gluten Challenge
Time Frame: Day 14
|
Peripheral blood mononuclear cells (PBMC) collected on Day 14 following gluten challenge were stained with phycoerythrin (PE)-labeled human leukocyte antigen (HLA)-DQ2.5:
gluten tetramers (DQ2.5-glia-α1 and DQ2.5-glia-α2) to identify antigen-specific cluster of differentiation (CD)4-positive thymus lymphocyte (T cells) reactive to gliadin (tetramer+ T cells) by flow cytometry.
PBMC were also labeled with a 20-antibody panel for cell surface antigen staining to further define tetramer+ T cell subsets.
Antigens included in the analysis were CD25, CD38, CD39, programmed cell death receptor 1 (PD-1), and integrin beta-7 (B7).
|
Day 14
|
Percentage of α1-gliadin-reactive CD4+ T Cells in Duodenal Biopsies After Gluten Challenge
Time Frame: Day 14
|
Lymphocytes from duodenal biopsies collected on Day 14 following gluten challenge were stained with a phycoerythrin (PE)-labeled human leukocyte antigen (HLA)-DQ2.5:
gluten tetramer (DQ2.5-glia-α1) to identify antigen-specific cluster of differentiation (CD)4-positive thymus lymphocyte (T cells) reactive to gliadin (tetramer+ T cells) by flow cytometry.
Lymphocytes were also labeled with a 20-antibody panel for cell surface antigen staining to further define tetramer+ T cell subsets.
Antigens included in the analysis were CD25, CD38, CD39, programmed cell death receptor 1 (PD-1), and integrin beta-7 (B7).
|
Day 14
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 28, 2020
Primary Completion (Actual)
June 23, 2021
Study Completion (Actual)
June 23, 2021
Study Registration Dates
First Submitted
August 5, 2019
First Submitted That Met QC Criteria
August 12, 2019
First Posted (Actual)
August 13, 2019
Study Record Updates
Last Update Posted (Estimate)
March 6, 2023
Last Update Submitted That Met QC Criteria
June 1, 2022
Last Verified
June 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0000-402
- MK-0000-402 (Other Identifier: Merck)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Celiac Disease
-
University of OxfordCompletedCeliac Disease | Mental Health Wellness 1 | Emotional Problem | Stigma, Social | Celiac Disease in Children | Celiac | DisclosureUnited Kingdom
-
IRCCS Burlo GarofoloRecruitingCeliac Disease in ChildrenItaly
-
Cairo UniversityNot yet recruitingCeliac Disease in Children
-
Meir Medical CenterTerminatedCeliac Disease in ChildrenIsrael
-
Schneider Children's Medical Center, IsraelUnknownCeliac Disease in ChildrenIsrael
-
University of PalermoCompletedNot-celiac Gluten (Wheat) SensitivityItaly
-
University of PalermoRecruiting
-
University of PalermoCompletedNot-celiac Gluten SensitivityItaly
-
ASST Fatebenefratelli SaccoNot yet recruiting
-
Leiden University Medical CenterZonMw: The Netherlands Organisation for Health Research and DevelopmentEnrolling by invitationCeliac Disease in ChildrenNetherlands
Clinical Trials on Gluten powder 4g
-
Sahlgrenska University Hospital, SwedenCompletedIrritable Bowel SyndromeSweden
-
Boston Children's HospitalChildren's Hospital Colorado; Celiac Disease FoundationRecruitingGastrointestinal Diseases | Celiac Disease | Malabsorption Syndromes | Digestive System Disease | Gluten Sensitivity | Intestinal Disease | Celiac Disease in ChildrenUnited States
-
Regeneron PharmaceuticalsRecruiting
-
Centre Hospitalier Eure-SeineNot yet recruiting
-
Massachusetts General HospitalTerminated
-
Yokohama City UniversityEA Pharma Co., Ltd.CompletedNonalcoholic Steatohepatitis | Nonalcoholic Fatty LiverJapan
-
University of Southern DenmarkOdense University Hospital; University Hospital Bispebjerg and Frederiksberg; Hospital of Southern Jutland and other collaboratorsNot yet recruitingInflammatory Bowel Diseases | Ulcerative ColitisDenmark
-
Yaqrit LtdAssistance Publique - Hôpitaux de Paris; IRCCS Azienda Ospedaliero-Universitaria... and other collaboratorsTerminatedLiver CirrhosisFrance, Italy, Portugal, Spain, United Kingdom, Switzerland
-
University Hospital, Clermont-FerrandCentre de Recherche en Nutrition Humaine d'Auvergne; Institut National de Recherche... and other collaboratorsCompleted
-
Göteborg UniversitySahlgrenska University Hospital, Sweden; University of Skövde; Ekhaga foundationRecruitingDiabetes | Celiac Disease | Metabolic Disease | AutoimmunitySweden